Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price & Analysis
Madrigal Pharmaceuticals, Inc. (MDGL) rose 2.06% to USD 476.89 as of June 9, 2026 at 23:52 UTC, according to Nexqual real-time market data.
MDGL last closed at USD 467.28; the session ranged USD 470.86–480.5 on volume of 285,809 shares. Market capitalization is $11.00B, with a 52-week range of USD 275–615 (NMS). Source: Nexqual, June 9, 2026 at 23:52 UTC.
Key Statistics (as of June 9, 2026 at 23:52 UTC)
| Price | USD 476.89 |
|---|---|
| Change | ▲ 2.06% (up) |
| Previous Close | USD 467.28 |
| Open | USD 474.52 |
| Day Range | USD 470.86 – 480.5 |
| 52-Week Range | USD 275 – 615 |
| Volume | 285,809 shares |
| Market Cap | $11.00B |
| Exchange | NMS |
Technical Analysis (MDGL)
Nexqual's technical model rates MDGL "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:52 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.45 (neutral) |
| vs SMA50 | Below (USD 514.56) |
| MACD | -10.2 (negative) |
Analyst Ratings (MDGL)
Wall Street analysts rate MDGL "Strong Buy" based on 14 analysts, with a mean price target of USD 679.29 (range USD 550–964), per Nexqual as of June 9, 2026 at 23:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 679.29 |
| High Target | USD 964 |
| Low Target | USD 550 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (MDGL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -2.23 |
| Revenue Estimate | $350.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.38 vs est -4.14 ▲ beat |
| 2025-12-31 | USD -2.57 vs est -0.88 ▼ miss |
| 2025-09-30 | USD -4.96 vs est -1.99 ▼ miss |
| 2025-06-30 | USD -1.9 vs est -3.53 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financials & Fundamentals (MDGL)
| Total Revenue | $1.13B |
|---|---|
| Revenue Growth (YoY) | +126.80% |
| Gross Margin | +93.07% |
| Operating Margin | -29.78% |
| Profit Margin | -27.32% |
| ROE | -49.35% |
| Debt / Equity | 63.91 |
| Current Ratio | 3.5 |
| Total Cash | $812.77M |
| Total Debt | $347.31M |
| Free Cash Flow | $-156.40M |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financial Health Score (MDGL)
Nexqual rates Madrigal Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:52 UTC.
| Growth | Strong — Revenue +432% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 93%, operating -30% |
| Balance Sheet | Strong — $813M cash vs $347M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$156M, burning cash |
| Efficiency | Critical — ROE -49%, ROA -17.6% |
Ownership (MDGL)
| Insider Ownership | +5.67% |
|---|---|
| Institutional Ownership | +106.28% |
| Shares Outstanding | 23.06M |
| Float | 13.79M |
| Short % of Float | +19.88% |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Leadership (MDGL)
Madrigal Pharmaceuticals, Inc. is led by William J. Sibold (age 59), CEO, President & Director, per Nexqual as of June 9, 2026 at 23:52 UTC.
| CEO, President & Director | William J. Sibold (age 59) |
|---|---|
| Founder, Senior Scientific & Medical Advisor and Director | Rebecca A. Taub (age 73) |
| Executive VP & CFO | Mardi C. Dier (age 61) |
| Executive Vice President of Business Planning & Operations | Mark Underwood |
Major Backers & Investors (MDGL)
Notable institutional backers of Madrigal Pharmaceuticals, Inc. include Baker Bros. Advisors, LP, Janus Henderson Group PLC, RTW Investments LP, according to Nexqual as of June 9, 2026 at 23:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 9.29% |
| Janus Henderson Group PLC | 8.76% |
| RTW Investments LP | 8.65% |
| Avoro Capital Advisors LLC | 7.89% |
| PAULSON & CO. INC. | 6.04% |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 3.69% |
| Wellington Management | 3.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.28% |
| BlackRock | 8.51% |
| State Street | 3.59% |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
From Madrigal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.
Partnerships
- In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.
- Blue Owl Credit Facility On July 17, 2025 (the "Closing Date"), we entered into the Financing Agreement with the Lenders and the Administrative Agent.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | USD 29.23 | ▲ 2.74% |
| AXSM | Axsome Therapeutics, Inc. | USD 245.64 | ▲ 5.73% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| KRYS | Krystal Biotech, Inc. | USD 309.75 | ▲ 2.91% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.86 | ▲ 1.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:52 UTC. This page is informational and not investment advice.